Evidence map›Paper›PMID 42459882›Full record

ArticleFrontiers in microbiology2026

Clinical characteristics, drug resistance profiles, and inflammatory cytokine signatures in newly treated versus retreated MDR/RR-TB patients: associations with treatment outcomes.

Yiyan Song, Dawei Yu, Junchi Xu, Yunxia Zhai, Huafeng Song, Hui Chen, Jianping Zhang, Ping Xu, Fanghua Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yiyan SongDepartment of Clinical Laboratory, The Fifth People's Hospital of Suzhou, The Affiliated Infectious Diseases Hospital of Soochow University, Suzhou, China.
Dawei YuDepartment of Clinical Laboratory, The Fifth People's Hospital of Suzhou, The Affiliated Infectious Diseases Hospital of Soochow University, Suzhou, China.
Junchi XuDepartment of Clinical Laboratory, The Fifth People's Hospital of Suzhou, The Affiliated Infectious Diseases Hospital of Soochow University, Suzhou, China.
Yunxia ZhaiDepartment of Clinical Laboratory, The Fifth People's Hospital of Suzhou, The Affiliated Infectious Diseases Hospital of Soochow University, Suzhou, China.
Huafeng SongDepartment of Clinical Laboratory, The Fifth People's Hospital of Suzhou, The Affiliated Infectious Diseases Hospital of Soochow University, Suzhou, China.
Hui ChenDepartment of Clinical Laboratory, The Fifth People's Hospital of Suzhou, The Affiliated Infectious Diseases Hospital of Soochow University, Suzhou, China.
Jianping ZhangDepartment of Tuberculosis, The Fifth People's Hospital of Suzhou, The Affiliated Infectious Diseases Hospital of Soochow University, Suzhou, China.
Ping XuDepartment of Clinical Laboratory, The Fifth People's Hospital of Suzhou, The Affiliated Infectious Diseases Hospital of Soochow University, Suzhou, China.
Fanghua LiDepartment of Clinical Laboratory, The Fifth People's Hospital of Suzhou, The Affiliated Infectious Diseases Hospital of Soochow University, Suzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) poses a significant threat to global tuberculosis control. Understanding drug resistance profiles, immune signatures, and their associations with treatment outcomes is critical. Methods: A total of 395 MDR/RR-TB patients were enrolled. Baseline characteristics, minimum inhibitory concentrations (MICs) for multiple anti-TB drugs, plasma inflammatory cytokine levels, and treatment outcomes were analyzed. Results: The cohort was predominantly male (69.6%), with a median age of 40 years. Pre-extensively drug-resistant (Pre-XDR-TB) accounted for 48.4%, and treatment success rate was 66.8%. Retreated patients showed significantly higher MICs for ethambutol, isoniazid, rifampicin, moxifloxacin, ofloxacin, and streptomycin (all Conclusion: In MDR/RR-TB patients, elevated ethambutol and isoniazid MICs were associated with treatment failure after multivariable adjustment; however, these associations were not significant after multiple comparisons correction. The potential prognostic value of quantitative MIC testing for these drugs remains to be established in future adequately powered studies.

Indexed as

cross-resistanceinflammatory cytokinesMDR/RR-TBMICtreatment outcome

Identifiers

PMID42459882
PMCPMC13368717

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.